Allogeneic NK cell infusion is promising, especially for cancer immunotherapy, due to the “missing self” hypothesis that states that NK cells are able to sense the absence of “self” MHC class I on target cells [10] whereas autologous NK cell activity is inhibited in cancer patients largely due to KIR-HLA matching [11]. This evidence concerns the gene KIR3DL1 and cancer.